DIANE-35 TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
23-03-2017
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
CYPROTERONE ACETATE; ETHINYL ESTRADIOL
から入手可能:
BAYER INC
ATCコード:
G03HB01
INN（国際名）:
CYPROTERONE AND ESTROGEN
投薬量:
2MG; 35MCG
医薬品形態:
TABLET
構図:
CYPROTERONE ACETATE 2MG; ETHINYL ESTRADIOL 35MCG
投与経路:
ORAL
パッケージ内のユニット:
21
処方タイプ:
Prescription
治療領域:
OTHER MISCELLANEOUS THERAPEUTIC AGENTS
製品概要:
Active ingredient group (AIG) number: 0232337001; AHFS:
認証ステータス:
APPROVED
承認日:
1997-09-17
製品の特徴
_DIANE-35 Product Monograph_
Page 1 of 44
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
DIANE
®
-35
cyproterone acetate and ethinyl estradiol tablets
2 mg cyproterone acetate and 0.035 mg ethinyl estradiol tablets
Acne Therapy
Bayer Inc.
Date of Revision:
2920 Matheson Boulevard East
March 16, 2017
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Submission Control No.: 201157
© 2017, Bayer Inc.
® TM see www.bayer.ca/tm-mc
_DIANE-35 Product Monograph_
Page 2 of 44
TABLE OF CONTENTS
PART
I:
HEALTH
PROFESSIONAL
INFORMATION ..........................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS...........................................................................................................
3
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
12
DRUG INTERACTIONS
.........................................................................................................
16
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
........................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
22
STORAGE AND STABILITY
.................................................................................................
23
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 23
PART
II:
SCIENTIFIC
INFORMATION
.....
完全なドキュメントを読む
